Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1987 Jan 15;136(2):121–127.

Adverse immunologic effects of antithyroid drugs.

S S Wing, I G Fantus
PMCID: PMC1492030  PMID: 3539299

Abstract

Propylthiouracil and methimazole are frequently used in the management of hyperthyroidism. Two patients in whom adverse immunologic effects other than isolated agranulocytosis developed during treatment with propylthiouracil are described. A review of the literature revealed 53 similar cases over a 35-year period. Rash, fever, arthralgias and granulocytopenia were the most common manifestations. Vasculitis, particularly with cutaneous manifestations, occurs and may be fatal. The clinical evidence suggests that an immunologic mechanism is involved. A number of different autoantibodies were reported, but antinuclear antibodies were infrequent, and none of the cases met the criteria for a diagnosis of systemic lupus erythematosus. Thus, the reactions do not represent a true drug-induced lupus syndrome. Current hypotheses and experimental data regarding the cause of the reactions are reviewed. No specific clinical subgroup at high risk can be identified, and manifestations may occur at any dosage and at any time during therapy. Cross-reactivity between the two antithyroid drugs can be expected. Except for minor symptoms (e.g., mild arthralgias or transient rash), such reactions are an indication for withdrawal of the drug and the use of alternative methods to control the hyperthyroidism. In rare cases of severe vasculitis a short course of high-dose glucocorticoid therapy may be helpful.

Full text

PDF
121

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amrhein J. A., Kenny F. M., Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr. 1970 Jan;76(1):54–63. doi: 10.1016/s0022-3476(70)80130-5. [DOI] [PubMed] [Google Scholar]
  2. Benson E. A., Ho P., Wang C., Wu P. C., Fredlund P. N., Yueng R. T. Insulin autoimmunity as a cause of hypoglycemia. Arch Intern Med. 1984 Dec;144(12):2351–2354. [PubMed] [Google Scholar]
  3. Berkman E. M., Orlin J. B., Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion. 1983 Mar-Apr;23(2):135–138. doi: 10.1046/j.1537-2995.1983.23283172851.x. [DOI] [PubMed] [Google Scholar]
  4. Bilezikian S. B., Laleli Y., Tsan M. F., Hodkinson B. A., Ice S., McIntyre P. A. Immunological: reactions involving leukocytes: III. Agranulocytosis induced by antithyroid drugs. Johns Hopkins Med J. 1976 Apr;138(4):124–129. [PubMed] [Google Scholar]
  5. Breese T. J., Solomon I. L. Granulocytopenia and hemolytic anemia as complications of propylthiouracil therapy. J Pediatr. 1975 Jan;86(1):117–119. doi: 10.1016/s0022-3476(75)80721-9. [DOI] [PubMed] [Google Scholar]
  6. Brohee D., Delespesse G., Debisschop M. J., Bonnyns M. Circulating immune complexes in various thyroid diseases. Clin Exp Immunol. 1979 Jun;36(3):379–383. [PMC free article] [PubMed] [Google Scholar]
  7. CRADDOCK C. G., Jr, SHOTTON D., CROCKETT C. L., LEAVELL B. S. Severe hypoprothrombinemia following propylthiouracil treatment of thyrotoxicosis. N Engl J Med. 1951 Apr 12;244(15):549–551. doi: 10.1056/NEJM195104122441504. [DOI] [PubMed] [Google Scholar]
  8. Calder E. A., Penhale W. J., Barnes E. W., Irvine W. J. Evidence for circulating immune complexes in thyroid disease. Br Med J. 1974 Apr 6;2(5909):30–31. doi: 10.1136/bmj.2.5909.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cassorla F. G., Finegold D. N., Parks J. S., Tenore A., Thawerani H., Baker L. Vasculitis, pulmonary cavitation, and anemia during antithyroid drug therapy. Am J Dis Child. 1983 Feb;137(2):118–122. doi: 10.1001/archpedi.1983.02140280016005. [DOI] [PubMed] [Google Scholar]
  10. Cetina J. A., Fishbein E., Alarcón-Segovia D. Antinuclear antibodies and propylthiouracil therapy. JAMA. 1972 May 15;220(7):1012–1012. [PubMed] [Google Scholar]
  11. Chan J. Y., Walfish P. G. Activated (Ia+) T-lymphocytes and their subsets in autoimmune thyroid diseases: analysis by dual laser flow microfluorocytometry. J Clin Endocrinol Metab. 1986 Feb;62(2):403–409. doi: 10.1210/jcem-62-2-403. [DOI] [PubMed] [Google Scholar]
  12. Chen B., Lang R., Jutrin Y., Ravid M. Recurrent agranulocytosis induced by two different antithyroid agents. Med J Aust. 1983 Jul 9;2(1):38–39. doi: 10.5694/j.1326-5377.1983.tb142086.x. [DOI] [PubMed] [Google Scholar]
  13. Cooper D. S., Goldminz D., Levin A. A., Ladenson P. W., Daniels G. H., Molitch M. E., Ridgway E. C. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983 Jan;98(1):26–29. doi: 10.7326/0003-4819-98-1-26. [DOI] [PubMed] [Google Scholar]
  14. Edell S. L., Bartuska D. G. Aplastic anemia secondary to methimazole-case report and review of hematologic side effects. J Am Med Womens Assoc. 1975 Oct;30(10):412–413. [PubMed] [Google Scholar]
  15. FEWELL R. A., ENGEL E. F., ZIMMERMAN S. L. Acute thrombopenic purpura associated with administration of propylthiouracil. J Am Med Assoc. 1950 Jul 8;143(10):891–892. doi: 10.1001/jama.1950.82910450001009. [DOI] [PubMed] [Google Scholar]
  16. Farbman K., Wheeler M. F., Glick S. M. Arthritis induced by antithyroid medication. N Y State J Med. 1969 Mar 15;69(6):826–831. [PubMed] [Google Scholar]
  17. Fedotin M. S., Lefer L. G. Liver disease caused by propylthiouracil. Arch Intern Med. 1975 Feb;135(2):319–321. [PubMed] [Google Scholar]
  18. GREENSTEIN R. H. Hypoprothrombinemia due to propylthiouracil therapy. JAMA. 1960 Jul 2;173:1014–1015. doi: 10.1001/jama.1960.73020270001010. [DOI] [PubMed] [Google Scholar]
  19. Gammeltoft M., Kristensen J. K. Propylthio-uracil-induced cutaneous vasculitis. Acta Derm Venereol. 1982;62(2):171–173. [PubMed] [Google Scholar]
  20. Goldrath N., Shoham J., Bank H., Eisenstein Z. Anti-thyroid drugs and lymphocyte function. II. The in vivo effect on blastogenesis and suppressor cell activity in Graves' disease. Clin Exp Immunol. 1982 Oct;50(1):62–69. [PMC free article] [PubMed] [Google Scholar]
  21. Griswold W. R., Mendoza S. A., Johnston W. Vasculitis associated with propylthiouracil. Evidence for immune complex pathogenesis and response to therapy. West J Med. 1978 Jun;128(6):543–546. [PMC free article] [PubMed] [Google Scholar]
  22. Harmon C. E., Portanova J. P. Drug-induced lupus: clinical and serological studies. Clin Rheum Dis. 1982 Apr;8(1):121–135. [PubMed] [Google Scholar]
  23. Hess E. V. Introduction to drug-related lupus. Arthritis Rheum. 1981 Aug;24(8):vi–ix. doi: 10.1002/art.1780240820. [DOI] [PubMed] [Google Scholar]
  24. Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet. 1983 Oct 29;2(8357):1037–1038. doi: 10.1016/s0140-6736(83)91031-0. [DOI] [PubMed] [Google Scholar]
  25. Houston B. D., Crouch M. E., Brick J. E., DiBartolomeo A. G. Apparent vasculitis associated with propylthiouracil use. Arthritis Rheum. 1979 Aug;22(8):925–928. doi: 10.1002/art.1780220819. [DOI] [PubMed] [Google Scholar]
  26. Hung W., August G. P. A "collagen-like" syndrome associated with antithyroid therapy. J Pediatr. 1973 May;82(5):852–854. doi: 10.1016/s0022-3476(73)80081-2. [DOI] [PubMed] [Google Scholar]
  27. Kampmann J. P., Hansen J. M. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet. 1981 Nov-Dec;6(6):401–428. doi: 10.2165/00003088-198106060-00001. [DOI] [PubMed] [Google Scholar]
  28. Kurtz M. D. Migratory polyarthritis occurring with methimazole therapy. N Y State J Med. 1968 Nov 1;68(21):2810–2811. [PubMed] [Google Scholar]
  29. Lam D. C., Lindsay R. H. Accumulation of 2-[14C]propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol. 1979 Aug 1;28(15):2289–2296. doi: 10.1016/0006-2952(79)90692-0. [DOI] [PubMed] [Google Scholar]
  30. Librik L., Sussman L., Bejar R., Clayton G. W. Thyrotoxicosis and collagen-like disease in three sisters of American Indian extraction. J Pediatr. 1970 Jan;76(1):64–68. doi: 10.1016/s0022-3476(70)80131-7. [DOI] [PubMed] [Google Scholar]
  31. MARTINEZ-LOPEZ J. I., GREENBERG S. E., KLING R. R. Drug-induced hepatic injury during methimazole therapy. Gastroenterology. 1962 Jul;43:84–87. [PubMed] [Google Scholar]
  32. McCORMICK R. V. Periarteritis occurring during propylthiouracil therapy. J Am Med Assoc. 1950 Dec 23;144(17):1453–1454. doi: 10.1001/jama.1950.62920170007008a. [DOI] [PubMed] [Google Scholar]
  33. McGregor A. M., Petersen M. M., McLachlan S. M., Rooke P., Smith B. R., Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 1980 Aug 7;303(6):302–307. doi: 10.1056/NEJM198008073030603. [DOI] [PubMed] [Google Scholar]
  34. Mihas A. A., Holley P., Koff R. S., Hirschowitz B. I. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology. 1976 May;70(5 PT1):770–774. [PubMed] [Google Scholar]
  35. Moreb J., Shemesh O., Shilo S., Manor C., Hershko C. Transient methimazole-induced bone marrow aplasia: in vitro evidence for a humoral mechanism of bone marrow suppression. Acta Haematol. 1983;69(2):127–131. doi: 10.1159/000206873. [DOI] [PubMed] [Google Scholar]
  36. Oh B. K., von Overveld G. P., Macfarlane J. D. Polyarthritis induced by propylthiouracil. Br J Rheumatol. 1983 May;22(2):106–108. doi: 10.1093/rheumatology/22.2.106. [DOI] [PubMed] [Google Scholar]
  37. Pacini F., Sridama V., Refetoff S. Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. J Endocrinol Invest. 1982 Nov-Dec;5(6):403–407. doi: 10.1007/BF03350541. [DOI] [PubMed] [Google Scholar]
  38. Papapetrou P. D., Mothon S., Alexander W. D. Binding of the 35-s of 35-s-propylthiouracil by follicular thyroglobulin in vivo and in vitro. Acta Endocrinol (Copenh) 1975 Jun;79(2):248–258. doi: 10.1530/acta.0.0790248. [DOI] [PubMed] [Google Scholar]
  39. Parker L. N. Letter: Hepatitis and propylthiouracil. Ann Intern Med. 1975 Feb;82(2):228–229. doi: 10.7326/0003-4819-82-2-228_2. [DOI] [PubMed] [Google Scholar]
  40. Reddy C. M. Propylthiouracil and hepatitis: a case report. J Natl Med Assoc. 1979 Dec;71(12):1185–1186. [PMC free article] [PubMed] [Google Scholar]
  41. Reidy T. J., Upshaw J. D., Jr, Chesney T. M. Propylthiouracil-induced vasculitis: a fatal case. South Med J. 1982 Oct;75(10):1297–1298. doi: 10.1097/00007611-198210000-00044. [DOI] [PubMed] [Google Scholar]
  42. Rosove M. H. Agranulocytosis and antithyroid drugs. West J Med. 1977 May;126(5):339–343. [PMC free article] [PubMed] [Google Scholar]
  43. Sammon T. J., Peden V. H., Witzleben C., King J. P. Disseminated intravascular coagulation complicating propylthiouracil therapy. A case description of a 16-year-old girl. Clin Pediatr (Phila) 1971 Dec;10(12):739–742. doi: 10.1177/000992287101001221. [DOI] [PubMed] [Google Scholar]
  44. Sanke T., Kondo M., Moriyama Y., Nanjo K., Iwo K., Miyamura K. Glucagon binding autoantibodies in a patient with hyperthyroidism treated with methimazole. J Clin Endocrinol Metab. 1983 Dec;57(6):1140–1144. doi: 10.1210/jcem-57-6-1140. [DOI] [PubMed] [Google Scholar]
  45. Searles R. P., Plymate S. R., Troup G. M. Familial thioamide-induced lupus syndrome in thyrotoxicosis. J Rheumatol. 1981 May-Jun;8(3):498–500. [PubMed] [Google Scholar]
  46. Shabtai R., Shapiro M. S., Orenstein D., Taragan R., Shenkman L. The antithyroid arthritis syndrome reviewed. Arthritis Rheum. 1984 Feb;27(2):227–229. doi: 10.1002/art.1780270216. [DOI] [PubMed] [Google Scholar]
  47. Spielberg S. P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc. 1984 May 15;43(8):2308–2313. [PubMed] [Google Scholar]
  48. Takuwa N., Kojima I., Ogata E. Lupus-like syndrome--a rare complication in thionamide treatment for Graves' disease. Endocrinol Jpn. 1981 Oct;28(5):663–667. doi: 10.1507/endocrj1954.28.663. [DOI] [PubMed] [Google Scholar]
  49. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  50. Vasily D. B., Tyler W. B. Propylthiouracil-induced cutaneous vasculitis. Case presentation and review of the literature. JAMA. 1980 Feb 1;243(5):458–461. doi: 10.1001/jama.243.5.458. [DOI] [PubMed] [Google Scholar]
  51. Verdy M., Pretty H., Cadotte M., Giroux J. M., Journet M. Vasculite secondaire aux antithyroïdiens. Union Med Can. 1975 Apr;104(4):576–579. [PubMed] [Google Scholar]
  52. WALZER R. A., EINBINDER J. Immunoleukopenia as an aspect of hypersensitivity to Propylthiouracil. JAMA. 1963 Jun 8;184:743–746. doi: 10.1001/jama.1963.03700230043006. [DOI] [PubMed] [Google Scholar]
  53. WING E. S., Jr, ASPER S. P., Jr Observations on the use of propylthiouracil in hyperthyroidism with especial reference to long-term treatment. Bull Johns Hopkins Hosp. 1952 Mar;90(3):201–227. [PubMed] [Google Scholar]
  54. Wall J. R., Fang S. L., Kuroki T., Ingbar S. H., Braverman L. E. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab. 1984 May;58(5):868–872. doi: 10.1210/jcem-58-5-868. [DOI] [PubMed] [Google Scholar]
  55. Wall J. R., Manwar G. L., Greenwood D. M., Walters B. A. The in vitro suppression of lectin induced 3H-thymidine incorporation into DNA of peripheral blood lymphocytes after the addition of propylthiouracil. J Clin Endocrinol Metab. 1976 Dec;43(6):1406–1409. doi: 10.1210/jcem-43-6-1406. [DOI] [PubMed] [Google Scholar]
  56. Weitzman S. A., Stossel T. P. Drug-induced immunological neutropenia. Lancet. 1978 May 20;1(8073):1068–1072. doi: 10.1016/s0140-6736(78)90915-7. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES